Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 2
2008 1
2009 4
2010 5
2011 3
2012 4
2013 1
2014 8
2015 10
2016 5
2017 10
2018 7
2019 9
2020 8
2021 11
2022 9
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. Suda G, et al. Among authors: natsuizaka m. J Med Virol. 2023 Feb;95(2):e28452. doi: 10.1002/jmv.28452. J Med Virol. 2023. PMID: 36597900
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, Yoda T, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Komukai S, Ogawa K, Sakamoto N. Sasaki T, et al. Among authors: natsuizaka m. Hepatol Res. 2023 Oct;53(10):960-967. doi: 10.1111/hepr.13936. Epub 2023 Jul 3. Hepatol Res. 2023. PMID: 37332115
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Hosoda S, et al. Among authors: natsuizaka m. Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun. Liver Cancer. 2022. PMID: 37325489 Free PMC article.
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N. Yang Z, et al. Among authors: natsuizaka m. Cancers (Basel). 2023 Jan 18;15(3):593. doi: 10.3390/cancers15030593. Cancers (Basel). 2023. PMID: 36765554 Free PMC article.
Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Tokuchi Y, et al. Among authors: natsuizaka m. Hepatol Res. 2023 Jul;53(7):595-606. doi: 10.1111/hepr.13899. Epub 2023 Apr 4. Hepatol Res. 2023. PMID: 36945790
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S, Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Yoshida S, et al. Among authors: natsuizaka m. Hepatol Res. 2022 Jul;52(7):603-613. doi: 10.1111/hepr.13765. Epub 2022 Apr 19. Hepatol Res. 2022. PMID: 35352857
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, Ando S, Shimazaki T, Izumi T, Umemura M, Kitagataya T, Shigesawa T, Suzuki K, Kimura M, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Ohnishi S, Sugiyama T, Takeda H, Sakamoto N. Nakamura A, et al. Among authors: natsuizaka m. Hepatol Res. 2022 Jun;52(6):508-521. doi: 10.1111/hepr.13757. Epub 2022 Feb 22. Hepatol Res. 2022. PMID: 35129841
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Hosoda S, Tokuchi Y, Kitagataya T, Ohara M, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Kawagishi N, et al. Among authors: natsuizaka m. Viruses. 2023 Jan 7;15(1):181. doi: 10.3390/v15010181. Viruses. 2023. PMID: 36680221 Free PMC article.
FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama M, Mizokami M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Okubo N, Ohnishi S, Takeda H, Sakamoto N. Maehara O, et al. Among authors: natsuizaka m. Cancer Biol Ther. 2021 Jun 3;22(5-6):372-380. doi: 10.1080/15384047.2021.1939638. Epub 2021 Jul 5. Cancer Biol Ther. 2021. PMID: 34224333 Free PMC article.
93 results